Table 2.
Cytotoxicity of anti–B-cell mAbs
| Cell line | No second antibody |
With GAH IgG second antibody |
||||
|---|---|---|---|---|---|---|
| IMMU-114 (HLA-DR) | Milatuzumab (CD74) | Veltuzumab (CD20) | IMMU-114 (HLA-DR) | Milatuzumab (CD74) | Veltuzumab (CD20) | |
| AML | ||||||
| GDM-1 | 106 ± 14 | 102 ± 15 | 100 ± 11 | 104 ± 10 | 129 ± 10 | 112 ± 15 |
| Kasumi-1 | 92 ± 6 | 84 ± 5 | 88 ± 16 | 89 ± 11 | 88 ± 9 | 99 ± 5 |
| Kasumi-3 | 120 ± 8 | 116 ± 7 | 112 ± 8 | 114 ± 10 | 123 ± 9 | 112 ± 18 |
| MCL | ||||||
| Jeko-1 | 41 ± 5* | 117 ± 10 | 124 ± 8 | 26 ± 2* | 33 ± 1* | 67 ± 3* |
| Granta-519 | 79 ± 3* | 104 ± 6 | 95 ± 3 | 65 ± 2* | 65 ± 3* | 65 ± 2* |
| ALL | ||||||
| RS4;11 | 78 ± 4 | 102 ± 10 | 88 ± 11 | 91 ± 10 | 89 ± 5 | 107 ± 6 |
| REH | 50 ± 5* | 79 ± 10 | 88 ± 7 | 29 ± 3* | 29 ± 2* | 95 ± 10 |
| 697 | 91 ± 13 | 105 ± 8 | 115 ± 12 | 58 ± 4* | 59 ± 8* | 124 ± 8 |
| MN60 | 35 ± 3* | 88 ± 15 | 92 ± 10 | 27 ± 3* | 35 ± 3* | 56 ± 2* |
| HCL | ||||||
| HC-1 | 28 ± 2* | 121 ± 6 | 91 ± 11 | 17 ± 1* | 19 ± 1* | 49 ± 10* |
| CLL | ||||||
| MEC-1 | 69 ± 3* | 100 ± 8 | 99 ± 5 | 30 ± 2* | 52 ± 2* | 63 ± 6* |
| WAC | 54 ± 7* | 97 ± 11 | 102 ± 17 | 41 ± 4* | 51 ± 7* | 62 ± 8* |
| NHL | ||||||
| Raji | 63 ± 11* | 89 ± 4 | 95 ± 5 | 10 ± 28 | 36 ± 3* | 76 ± 10* |
| RL | 11 ± 1* | 126 ± 4 | 100 ± 16 | 20 ± 0* | 31 ± 3* | 56 ± 5* |
| MM | ||||||
| CAG | 69 ± 10* | 90 ± 21 | 82 ± 11 | 51 ± 11* | 67 ± 15* | 79 ± 8 |
| KMS-11 | 31 ± 4* | 89 ± 15 | 88 ± 3 | 21 ± 1* | 22 ± 5* | 63 ± 14 |
Values are percentage of untreated values in MTT assay.
*
Statistically significant (P < .05) decrease of 20% or more.